Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

perrigo co. plc - PRGO

PRGO

Close Chg Chg %
9.64 0.04 0.41%

Closed Market

9.68

+0.04 (0.41%)

Volume: 2.50M

Last Updated:

Mar 25, 2026, 3:59 PM EDT

Trade Now

Company Overview: perrigo co. plc - PRGO

PRGO Key Data

Open

$9.91

 Day Range

9.43 - 9.99

52 Week Range

9.23 - 28.44

 Market Cap

$1.33B

Shares Outstanding

137.65M

 Public Float

137.03M

Beta

0.41

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$10.28

Yield

1,203.32%

 Dividend

$0.29

EX-DIVIDEND DATE

Mar 2, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

4.60M

  

PRGO Performance

1 Week
 
 4.22%
 
1 Month
 
 -27.08%
 
3 Months
 
 -30.25%
 
1 Year
 
 -65.65%
 
5 Years
 
 -77.05%
 

PRGO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About perrigo co. plc - PRGO

Perrigo Co. Plc is a pure-play self-care company provider of consumer self-care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

PRGO At a Glance

Perrigo Co. Plc
The Sharp Building
Dublin, Dublin 2/74
Phone 353-1-709-4000 Revenue 4.25B
Industry Pharmaceuticals: Major Net Income -1,425,400,000.00
Sector Health Technology Employees 8,100
Fiscal Year-end 12 / 2026
View SEC Filings

PRGO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.453
Price to Book Ratio 0.652
Price to Cash Flow Ratio 8.08
Enterprise Value to EBITDA 7.649
Enterprise Value to Sales 1.226
Total Debt to Enterprise Value 0.732

PRGO Efficiency

Revenue/Employee 525,086.42
Income Per Employee -175,975.309
Receivables Turnover 6.542
Total Asset Turnover 0.468

PRGO Liquidity

Current Ratio 2.762
Quick Ratio 1.627
Cash Ratio 0.525

PRGO Profitability

Gross Margin 35.157
Operating Margin 8.09
Pretax Margin -30.516
Net Margin -33.514
Return on Assets -15.424
Return on Equity -38.658
Return on Total Capital -20.766
Return on Invested Capital -19.02

PRGO Capital Structure

Total Debt to Total Equity 130.043
Total Debt to Total Capital 56.53
Total Debt to Total Assets 44.725
Long-Term Debt to Equity 127.92
Long-Term Debt to Total Capital 55.607
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Perrigo Co. Plc - PRGO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
4.45B 4.66B 4.37B 4.25B
Sales Growth
+7.47% +4.60% -6.04% -2.76%
Cost of Goods Sold (COGS) incl D&A
2.99B 2.98B 2.83B 2.76B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
338.60M 359.50M 325.90M 337.50M
Depreciation
86.20M 93.70M 97.40M 114.80M
Amortization of Intangibles
252.40M 265.80M 228.50M 222.70M
COGS Growth
+9.82% -0.51% -4.87% -2.58%
Gross Income
1.46B 1.68B 1.54B 1.50B
Gross Income Growth
+2.96% +15.08% -8.12% -3.09%
Gross Profit Margin
+32.79% +36.07% +35.28% +35.16%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.29B 1.40B 1.22B 1.15B
Research & Development
123.10M 122.50M 112.20M 95.40M
Other SG&A
1.16B 1.27B 1.11B 1.06B
SGA Growth
+7.86% +8.61% -12.33% -6.01%
Other Operating Expense
- - - -
-
Unusual Expense
140.40M 97.30M 173.10M 1.40B
EBIT after Unusual Expense
32.60M 184.90M 145.00M (1.05B)
Non Operating Income/Expense
(26.40M) 31.50M 22.80M (28.20M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
(1.50M) (1.90M) (1.50M) (300.00K)
Interest Expense
145.30M 224.70M 248.50M 216.00M
Interest Expense Growth
+20.58% +54.65% +10.59% -13.08%
Gross Interest Expense
145.30M 224.70M 248.50M 216.00M
Interest Capitalized
- - - -
-
Pretax Income
(139.10M) (8.30M) (80.70M) (1.30B)
Pretax Income Growth
-153.77% +94.03% -872.29% -1,508.30%
Pretax Margin
-3.13% -0.18% -1.85% -30.52%
Income Tax
(8.20M) (3.90M) 80.00M 104.40M
Income Tax - Current - Domestic
(7.80M) 18.20M 30.40M 133.90M
Income Tax - Current - Foreign
33.60M 58.60M 59.30M 11.20M
Income Tax - Deferred - Domestic
(8.60M) (12.90M) 27.60M (37.40M)
Income Tax - Deferred - Foreign
(25.40M) (67.80M) (37.30M) (3.30M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(1.50M) (1.90M) (1.50M) (300.00K)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(130.90M) (4.40M) (160.70M) (1.40B)
Minority Interest Expense
- - - -
-
Net Income
(130.90M) (4.40M) (160.70M) (1.40B)
Net Income Growth
- +96.64% -3,552.27% -772.62%
Net Margin Growth
-2.94% -0.09% -3.67% -32.97%
Extraordinaries & Discontinued Operations
(9.70M) (8.30M) (11.10M) (23.10M)
Discontinued Operations
(9.70M) (8.30M) (11.10M) (23.10M)
Net Income After Extraordinaries
(140.60M) (12.70M) (171.80M) (1.43B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(140.60M) (12.70M) (171.80M) (1.43B)
EPS (Basic)
-1.0454 -0.0939 -1.2504 -10.2917
EPS (Basic) Growth
-19.98% +91.02% -1,231.63% -723.07%
Basic Shares Outstanding
134.50M 135.30M 137.40M 138.50M
EPS (Diluted)
-1.0454 -0.0939 -1.2504 -10.2917
EPS (Diluted) Growth
-19.98% +91.02% -1,231.63% -723.07%
Diluted Shares Outstanding
134.50M 135.30M 137.40M 138.50M
EBITDA
511.60M 641.70M 644.00M 681.60M
EBITDA Growth
-4.73% +25.43% +0.36% +5.84%
EBITDA Margin
+11.50% +13.78% +14.72% +16.03%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 18.667
Number of Ratings 6 Current Quarters Estimate 0.333
FY Report Date 03 / 2026 Current Year's Estimate 2.28
Last Quarter’s Earnings 0.77 Median PE on CY Estimate N/A
Year Ago Earnings 2.75 Next Fiscal Year Estimate 2.443
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 4 3
Mean Estimate 0.33 0.39 2.28 2.44
High Estimates 0.36 0.42 2.80 2.50
Low Estimate 0.29 0.38 2.07 2.38
Coefficient of Variance 11.36 5.87 15.27 2.47

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 1 1 0
HOLD 3 3 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Perrigo Co. Plc - PRGO

Date Name Shares Transaction Value
Mar 18, 2026 Geoffrey M. Parker Director 3,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 18, 2026 Bradley A. Alford Director 3,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Robert Willis EVP & CHRO 47,935 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 513,863.20
Mar 11, 2026 Patrick Lockwood-Taylor CEO; Director 11,727 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Patrick Lockwood-Taylor CEO; Director 102,135 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 1,094,887.20
Mar 11, 2026 Patrick Lockwood-Taylor CEO; Director 107,138 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $10.72 per share 1,148,519.36
Mar 11, 2026 Patrick Lockwood-Taylor CEO; Director 93,299 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 1,000,165.28
Mar 11, 2026 Patrick Lockwood-Taylor CEO; Director 97,539 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 1,045,618.08
Mar 11, 2026 Robert Willis EVP & CHRO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Robert Willis EVP & CHRO 2,742 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Robert Willis EVP & CHRO 52,113 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $10.72 per share 558,651.36
Mar 11, 2026 Robert Willis EVP & CHRO 44,094 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 472,687.68
Mar 11, 2026 Robert Willis EVP & CHRO 45,010 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 482,507.20
Mar 11, 2026 Robert Willis EVP & CHRO 43,252 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 463,661.44
Mar 11, 2026 Robert Willis EVP & CHRO 44,682 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 478,991.04
Mar 11, 2026 Jonas Samuelson Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2026 Jonas Samuelson Director 1,318 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 14,128.96
Mar 11, 2026 Jonas Samuelson Director 3,066 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $10.72 per share 32,867.52
Sep 10, 2025 Charles Atkinson EVP, General Counsel & Sec. 1,000 Open market or private purchase of non-derivative security Non-derivative transaction at $23.2 per share 23,200.00
Jul 11, 2025 Roberto Khoury EVP and President of CSCI 2,211 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Perrigo Co. Plc in the News